# Angela DeMichele

Source: https://onco.cc/people/angela-demichele/  
OnCo record `angela-demichele` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.

## Summary

Angela DeMichele is Co-Leader of the Breast Cancer Research Program and the Alan and Jill Miller Professor in Breast Cancer Excellence at the Abramson Cancer Center, University of Pennsylvania. She is a medical oncologist known for conducting the first palbociclib clinical trial in breast cancer and for co-leading the I-SPY 2 adaptive platform trial. Her selected paper reports the phase 2 activity, safety and predictive biomarkers of the CDK4/6 inhibitor palbociclib in Rb-positive advanced breast cancer. She now studies disseminated tumour cell dormancy as a target for preventing late recurrence in hormone receptor-positive and triple-negative breast cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Co-Leader, Breast Cancer Research Program; Alan and Jill Miller Professor in Breast Cancer Excellence
- Specialisms: Breast cancer; CDK4/6 inhibitors; I-SPY 2 platform trial; Dormancy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=DeMichele%20A%5BAuthor%5D

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/)
- drugs: [Palbociclib](https://onco.cc/drugs/palbociclib/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://onco.cc/institutions/penn-abramson/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/)

---
JSON: https://onco.cc/api/v1/entities/angela-demichele.json